Evan Loh

Dr. Evan Loh currently serves as Chief Executive Officer of Paratek Pharmaceuticals, a role he has held since 2019, and has been a member of Paratek’s Board of Directors since 2012. He has extensive leadership experience in biopharmaceutical drug development, commercial and corporate operations.
Previously, Dr. Loh held leadership positions at Pfizer, including Senior Vice President of Development and Strategic Operations, Worldwide Research and Development where he oversaw scientific, operational and strategic drug development initiatives and led global portfolio prioritization. Prior to that, he was Vice President, Multiple Therapeutic Areas at Wyeth Pharmaceuticals, leading global development strategies for multiple successful regulatory approvals, including Torisel and Tygacil.
Dr. Loh is currently a board member of IntegerBio and, in the past, has served as a board member of Eiger Biopharmaceuticals, Inc., Adaptive Phage Therapeutics, Windtree Pharmaceuticals, Inc. and Nivalis Therapeutics, Inc. Dr. Loh was Chairman of the Antimicrobials Working Group, an industry leading coalition of biotech companies focused on antimicrobial development from 2019 to 2021.
Dr. Loh received his A.B. from Harvard College and his M.D. from Harvard Medical School. He completed his residency and fellowship training in Internal Medicine and Cardiovascular Medicine at Brigham and Women’s Hospital. His academic appointments include faculty positions at Harvard Medical School and the University of Pennsylvania School of Medicine.